Diagnostic accuracy of HPV16 early antigen serology for HPV-driven oropharyngeal cancer is independent of age and sex
© 2023 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC..
A growing proportion of head and neck cancer (HNC), especially oropharyngeal cancer (OPC), is caused by human papillomavirus (HPV). There are several markers for HPV-driven HNC, one being HPV early antigen serology. We aimed to investigate the diagnostic accuracy of HPV serology and its performance across patient characteristics. Data from the VOYAGER consortium was used, which comprises five studies on HNC from North America and Europe. Diagnostic accuracy, that is, sensitivity, specificity, Cohen's kappa and correctly classified proportions of HPV16 E6 serology, was assessed for OPC and other HNC using p16INK4a immunohistochemistry (p16), HPV in situ hybridization (ISH) and HPV PCR as reference methods. Stratified analyses were performed for variables including age, sex, smoking and alcohol use, to test the robustness of diagnostic accuracy. A risk-factor analysis based on serology was conducted, comparing HPV-driven to non-HPV-driven OPC. Overall, HPV serology had a sensitivity of 86.8% (95% CI 85.1-88.3) and specificity of 91.2% (95% CI 88.6-93.4) for HPV-driven OPC using p16 as a reference method. In stratified analyses, diagnostic accuracy remained consistent across sex and different age groups. Sensitivity was lower for heavy smokers (77.7%), OPC without lymph node involvement (74.4%) and the ARCAGE study (66.7%), while specificity decreased for cases with <10 pack-years (72.1%). The risk-factor model included study, year of diagnosis, age, sex, BMI, alcohol use, pack-years, TNM-T and TNM-N stage. HPV serology is a robust biomarker for HPV-driven OPC, and its diagnostic accuracy is independent of age and sex. Future research is suggested on the influence of smoking on HPV antibody levels.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:154 |
|---|---|
| Enthalten in: |
International journal of cancer - 154(2024), 2 vom: 15. Jan., Seite 389-402 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kusters, Johannes M A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Diagnostic accuracy |
|---|
| Anmerkungen: |
Date Completed 27.11.2023 Date Revised 24.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/ijc.34710 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361917600 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361917600 | ||
| 003 | DE-627 | ||
| 005 | 20240324234807.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ijc.34710 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1344.xml |
| 035 | |a (DE-627)NLM361917600 | ||
| 035 | |a (NLM)37694289 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kusters, Johannes M A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Diagnostic accuracy of HPV16 early antigen serology for HPV-driven oropharyngeal cancer is independent of age and sex |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.11.2023 | ||
| 500 | |a Date Revised 24.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC. | ||
| 520 | |a A growing proportion of head and neck cancer (HNC), especially oropharyngeal cancer (OPC), is caused by human papillomavirus (HPV). There are several markers for HPV-driven HNC, one being HPV early antigen serology. We aimed to investigate the diagnostic accuracy of HPV serology and its performance across patient characteristics. Data from the VOYAGER consortium was used, which comprises five studies on HNC from North America and Europe. Diagnostic accuracy, that is, sensitivity, specificity, Cohen's kappa and correctly classified proportions of HPV16 E6 serology, was assessed for OPC and other HNC using p16INK4a immunohistochemistry (p16), HPV in situ hybridization (ISH) and HPV PCR as reference methods. Stratified analyses were performed for variables including age, sex, smoking and alcohol use, to test the robustness of diagnostic accuracy. A risk-factor analysis based on serology was conducted, comparing HPV-driven to non-HPV-driven OPC. Overall, HPV serology had a sensitivity of 86.8% (95% CI 85.1-88.3) and specificity of 91.2% (95% CI 88.6-93.4) for HPV-driven OPC using p16 as a reference method. In stratified analyses, diagnostic accuracy remained consistent across sex and different age groups. Sensitivity was lower for heavy smokers (77.7%), OPC without lymph node involvement (74.4%) and the ARCAGE study (66.7%), while specificity decreased for cases with <10 pack-years (72.1%). The risk-factor model included study, year of diagnosis, age, sex, BMI, alcohol use, pack-years, TNM-T and TNM-N stage. HPV serology is a robust biomarker for HPV-driven OPC, and its diagnostic accuracy is independent of age and sex. Future research is suggested on the influence of smoking on HPV antibody levels | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a diagnostic accuracy | |
| 650 | 4 | |a head and neck cancer | |
| 650 | 4 | |a human papillomavirus | |
| 650 | 4 | |a oropharyngeal cancer | |
| 650 | 4 | |a serology | |
| 700 | 1 | |a Diergaarde, Brenda |e verfasserin |4 aut | |
| 700 | 1 | |a Ness, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Schim van der Loeff, Maarten F |e verfasserin |4 aut | |
| 700 | 1 | |a Heijne, Janneke C M |e verfasserin |4 aut | |
| 700 | 1 | |a Schroeder, Lea |e verfasserin |4 aut | |
| 700 | 1 | |a Hueniken, Katrina |e verfasserin |4 aut | |
| 700 | 1 | |a McKay, James D |e verfasserin |4 aut | |
| 700 | 1 | |a Macfarlane, Gary J |e verfasserin |4 aut | |
| 700 | 1 | |a Lagiou, Pagona |e verfasserin |4 aut | |
| 700 | 1 | |a Lagiou, Areti |e verfasserin |4 aut | |
| 700 | 1 | |a Polesel, Jerry |e verfasserin |4 aut | |
| 700 | 1 | |a Agudo, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Alemany, Laia |e verfasserin |4 aut | |
| 700 | 1 | |a Ahrens, Wolfgang |e verfasserin |4 aut | |
| 700 | 1 | |a Healy, Claire M |e verfasserin |4 aut | |
| 700 | 1 | |a Conway, David I |e verfasserin |4 aut | |
| 700 | 1 | |a Robinson, Max |e verfasserin |4 aut | |
| 700 | 1 | |a Canova, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Holcátová, Ivana |e verfasserin |4 aut | |
| 700 | 1 | |a Richiardi, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Znaor, Ariana |e verfasserin |4 aut | |
| 700 | 1 | |a Pring, Miranda |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Steve |e verfasserin |4 aut | |
| 700 | 1 | |a Hayes, D Neil |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Geoffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Hung, Rayjean J |e verfasserin |4 aut | |
| 700 | 1 | |a Brennan, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Olshan, Andrew F |e verfasserin |4 aut | |
| 700 | 1 | |a Virani, Shama |e verfasserin |4 aut | |
| 700 | 1 | |a Waterboer, Tim |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of cancer |d 1966 |g 154(2024), 2 vom: 15. Jan., Seite 389-402 |w (DE-627)NLM000004383 |x 1097-0215 |7 nnns |
| 773 | 1 | 8 | |g volume:154 |g year:2024 |g number:2 |g day:15 |g month:01 |g pages:389-402 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ijc.34710 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 154 |j 2024 |e 2 |b 15 |c 01 |h 389-402 | ||